USPTO serial 78280590
KANION
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 1, 2005
- Examiner
- CHICOSKI, JENNIFER D
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.
Need help with KANION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jiangsu Kanion Pharmaceutical Co., Ltd.
Jiangsu, CN
Other trademarks owned by Jiangsu Kanion Pharmaceutical Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Jiangsu, CN
Other trademarks owned by Jiangsu Kanion Pharmaceutical Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Jiangsu, CN
Other trademarks owned by Jiangsu Kanion Pharmaceutical Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Prakash NAMA
121 Moore StPrinceton, NJ 08540United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for the treatment of gynecological diseases, obstetric diseases, bleeding after induced abortion, abdominal pain after insertion of intrauterine contraceptive device, mammary diseases, diseases of the urogenital tract, spondylitis, osteoarthritis, arthritis, painful heel, osteoarthrosis deformans endemica, hemicrania, cluster headache, tensional headache, hyperlipemia, blood hyperviscosity, brain trauma syndrome, vertigo, atherosclerosis, premonitory apoplexy, ischemic apoplexy and its sequela, gastrointestinal disease, deficiency of kidney-yin, lumbago, painful legs, neurasthenia, cardiovascular diseases, cerebrovascular diseases, menopause syndrome, excessive blood lipid, irregular flow of Qi, hypochondriac pain, dysmenorrheal, influenza, inflammation of the upper respiratory tract, pharyngitis, pneumonia and epidemic parotitis, wind-cold headache, pain in the supra-orbital bone, distention and pain due to nasal sinusitis, wind-damp headache and nervous headache; Chinese medicines for the treatment of gynecological diseases, obstetric diseases, bleeding after induced abortion, abdominal pain after insertion of intrauterine contraceptive device, mammary diseases, diseases of the urogenital tract, spondylitis, osteoarthritis, arthritis, painful heel, osteoarthrosis deformans endemica, hemicrania, cluster headache, tensional headache, hyperlipemia, blood hyperviscosity, brain trauma syndrome, vertigo, atherosclerosis, premonitory apoplexy, ischemic apoplexy and its sequela, gastrointestinal disease, deficiency of kidney-yin, lumbago, painful legs, neurasthenia, cardiovascular diseases, cerebrovascular diseases, menopause syndrome, excessive blood lipid, irregular flow of Qi, hypochondriac pain, dysmenorrheal, influenza, inflammation of the upper respiratory tract, pharyngitis, pneumonia and epidemic parotitis, wind-cold headache, pain in the supra-orbital bone, distention and pain due to nasal sinusitis, wind-damp headache and nervous headache; nutritional supplements; baby food; medicinal preparations in liquid form for dissolving cholesterol, medicinal preparations in liquid form for softening and expanding blood vessels, medicinal preparations in liquid form for removing blood lipid, medicinal preparations in liquid form for the treatment of hypertension, hyperlipemia, senile dementia, coronary heart disease, atherosclerosis, hyperlipemia; ginseng for medicinal use; medicinal tea for weight-loss; herbal teas for medicinal purposes; dietary supplement tablets for the use of anti-fatigue, protecting the liver against chemical lesion, improving the blood circulation, smoothing the skin, refreshing the mind, invigorating vital energy, promoting metabolism, improving immunity and regulating bilaterally the functional balance of human body; food supplements; nutritional supplements; nutritionally fortified beverages; and surgical dressings | ACTIVE | Aug 12, 2000 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Jiangsu Kanion Pharmaceutical Co., Ltd.
- Other trademarks owned by Jiangsu Kanion Pharmaceutical Co., Ltd.
- Other trademarks owned by Jiangsu Kanion Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named KANION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2024 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Aug 10, 2024 | RNL2 | REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Aug 10, 2024 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jul 30, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 9, 2024 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Mar 1, 2024 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Jul 10, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 9, 2014 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| May 9, 2014 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| May 9, 2014 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| May 9, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 28, 2014 | 89AF | REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED | — |
| Apr 28, 2014 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Apr 28, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 22, 2010 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Oct 18, 2010 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 14, 2010 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Aug 25, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 25, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 25, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 25, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 2, 2008 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 2, 2008 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 1, 2005 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 7, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 17, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Sep 30, 2004 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 13, 2004 | ALIE | ASSIGNED TO LIE | — |
| Sep 9, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 27, 2004 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 11, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 11, 2004 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 12, 2004 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2004 | DOCK | ASSIGNED TO EXAMINER | — |